The United States has approved Lenacapavir, marketed as Sunlenca or Yeztugo, a groundbreaking new drug that offers near-complete protection (99.99%) against HIV with just two injections per year. Developed by Gilead Sciences, the drug has been hailed as a major milestone in the fight against HIV. To ensure wider access, Gilead has signed royalty-free licensing agreements with six generic manufacturers, enabling affordable global distribution. Lenacapavir has proven nearly 100% effective in preventing HIV infections, a virus that still affects approximately 1.3 million people annually. In recognition of its impact, the scientific journal Science named it the "Breakthrough of the Year" in 2024.